Lab Invest 2008, 88: 686–693.CrossRefPubMed 4. Dalbagni G: The Management of Superficial Bladder Cancer. Nat Clin Pract Urol 2007, 4: 254–260.CrossRefPubMed 5. Choueiri T, Raghavan D: Chemotherapy for muscle-invasive bladder cancer treated with definitive BLZ945 supplier radiotherapy persisting uncertainties. Nat Clin Pract Oncol 2008, 5: 444–454.CrossRefPubMed 6. Sternberg CN, Donat SM, Bellmunt

J, Millikan RE, Stadler W, De Mulder P, Sherif A, Maase H, Tsukamoto T, Soloway MS: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007, 69: 62–79.CrossRefPubMed 7. Wan X, Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 2007, 12: 1007–1018.CrossRefPubMed 8. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent BB-94 in vivo J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL: Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Med 2008, 5: e21.CrossRef JQEZ5 order 9. Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P, Oliveira J, Criado B, Lopes C: Ki-67 index enhances the prognostic accuracy of the urothelial superficial

bladder carcinoma risk group classification. Int J Cancer 2003, 105: 267–272.CrossRefPubMed 10. Pignot G, Bieche I, Vacher S, Güet C, Vieillefond A, Debré B, Lidereau R, Amsellem-Ouazana D: Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways Thiamet G in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker. Eur Urol 2008, in press. doi:10.1016/j.eururo.2008.05.027PubMed 11. Huang S, Houghtoun PJ: Inhibitors of mammalian target of rapamycin as a novel agents: from bench to clinic. Curr Opinion Invest Drugs 2002, 3: 295–304. 12. Dutcher JP: Mammalian target of rapamycin inhibition. Clin Cancer Res 2004, 10: 6382–6387.CrossRef 13. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene

2000, 27: 6680–6686.CrossRef 14. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001, 7: 1758–1764.PubMed 15. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001, 8: 249–258.CrossRefPubMed 16. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004, 24: 200–216.CrossRefPubMed 17.